This trial is testing a new drug for people with cancer that has no standard treatment. The goal is to see if it is safe and tolerated.
- Solid Tumors
- Solid Metastatic Tumor
- Advanced Cancer
2 Primary · 8 Secondary · Reporting Duration: Baseline up to approximately 3 years
Awards & Highlights
1 Treatment Group
Dose Escalation (DS-1055a)
1 of 1
40 Total Participants · 1 Treatment Group
Primary Treatment: DS-1055a · No Placebo Group · Phase 1
Who is running the clinical trial?
Age 18+ · All Participants · 2 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Has DS-1055a been accepted for regulatory use by the Food and Drug Administration?
"Due to the limited data available, DS-1055a's safety rating is 1. This reflects it being a Phase One trial with little evidence of efficacy and security." - Anonymous Online Contributor
Are there any openings in this clinical experiment available to participants?
"Affirmative. According to the clinicaltrials.gov database, this experiment is presently seeking out participants and has been accepting applications since October 9th 2020. The most up-to-date update was on November 28th 2022. 40 patients need to be recruited from a single site for this trial." - Anonymous Online Contributor
How many participants are taking part in this clinical research?
"Affirmative. The information contained on clinicaltrials.gov confirms that this experiment, which was initially published on October 9th 2020, is actively recruiting participants. Approximately 40 people need to be enrolled from a single medical centre." - Anonymous Online Contributor